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Tumors of the kidney, bladder, prostate, testis, and adrenal represent a large part of the
adult urologic practice, but are relatively infrequent in children.The natural history and man-
agement of these tumors in the pediatric age is different from that of the adults. As result
of the successful work of several clinical trial groups in recent decades, there has been a
significant improvement in their cure rates. The aim of this article is to review their most
significant clinical aspects, as well as to present an update in their management.
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KIDNEY TUMORS
Among the primary pediatric kidney tumors, the most frequent is
the Wilms tumor (WT), followed by the mesoblastic nephroma.
The incidence of the different tumors is shown in Table 1 (1, 2).
WILMS TUMOR
Wilms tumor or nephroblastoma is the most common genitouri-
nary malignant tumor of children. The incidence in the United
States is seven per million children below 15 years of age, while
in different regions of Brazil it varies from 4 to 15 cases per mil-
lion per year. The peak incidence occurs between 2 and 3 years of
age (3, 4).
Mutations or deletions of the WT1 gene of the 11p13 locus are
present in 15–20% of sporadic tumors, while theWTX gene shows
mutations in 29% of them. Loss of heterozygosity (LOH) of the 1p
and/or 16q chromosomes is a factor of adverse prognosis (5). Loss
of imprinting (LOI) or LOH at 11p15 leads to IGF2 overexpres-
sion and is present in 70% of WT patients. Some syndromes and
conditions are associated to WT gene mutations and to the pres-
ence of intralobar and perilobar nephrogenic rests, leading to an
increased risk of developing WT, such as Beckwith–Wiedemann,
Denys–Drash, WAGR, and corporal hemihypertrophy (6, 7).
The majority of WT is characterized by a triphasic histol-
ogy, that includes blastematous, epithelial, and stromal com-
ponents. The most important histological factor in progno-
sis is the occurrence of anaplasia, which is observed in 5%
of the cases and is characterized by the presence of multiple
mitoses, as well as increase in size and hyperchromasia of the
cell nucleus. Its presence, either focal or diffuse, indicates an
increased aggressiveness of the tumor, even if it is still localized, as
in stages I and II (8).
In general, WT manifests itself as an asymptomatic abdominal
mass, which is palpated by the parents or caretakers in 90% of the
cases. Macroscopic hematuria occurs in 25% of cases. Abdominal
pain is referred in 30%, while high blood pressure is observed
in about 25% of the patients. Up to 12% of patients with WT
have associated congenital abnormalities, such as cryptorchidism,
hypospadias, hemihypertrophy, and aniridia (9). Between 5 and
15% of patients have bilateral or multicentric tumors. The average
age at presentation is 42–47 months for patients with unilateral
tumors and 30–33 months for those with bilateral tumors (7).
Usually, the abdominal ultrasound (US) examination confirms
the presence of a renal mass, but computer tomography (CT) is
used to provide all information required for adequate diagnosis
and staging of this tumor, including infiltration of adjacent struc-
tures, extension to the inferior vena cava or abdominal or thoracic
metastases (7). In some cases, Doppler US or magnetic resonance
imaging (MRI) may be necessary to confirm involvement of the
renal veins and cava. Differential diagnosis includes neuroblas-
toma, which often occurs in children of the same age. The staging
system for WT is presented in Table 2 (10).
Treatment of WT includes surgery, chemotherapy, and in some
patients radiotherapy. There are two treatment protocols for the
initial management of this tumor. One, recommended by the
Children’s Oncology Group (COG) advocates up-front surgical
removal without interference of neoadjuvant antineoplastic drugs,
thus providing a detailed histological staging and accurate cytoge-
netic studies, necessary for planning post-operative treatment. The
other protocol is proposed by the International Society for Pedi-
atric Oncology (SIOP), which advocates 4–6 weeks of chemother-
apy before nephrectomy, with or without concomitant metastases.
Despite the potential adverse effect of neoadjuvant chemother-
apy in staging and histologic evaluation, its beneficial effects are
the reduction of the tumoral size and the formation of a fibrous
pseudocapsule that facilitate the surgical removal and decrease the
risks of rupture and spillage during surgery.
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Table 1 | Pediatric kidney tumors: classification and frequency (1).
Histological type Frequency (%)
Wilms’ tumor 85
Mesoblastic nephroma 5
Clear cell sarcoma 4
Rhabdoid tumor 2
Miscellaneous 4
Table 2 | Wilms tumor staging system (10).
I – tumor restricted to the kidney, completely excised, no penetration of
the capsule or involvement of renal sinus vessels
II – tumor beyond the kidney, but without residual beyond the margins of
excision. Eventual tumoral thrombus outside the kidney, but completely
removed en-bloc with the tumor
III – gross or microscopic residual local tumor postoperatively, including
positive margins, inoperable tumor, intra-abdominal lymph node
metastasis, peritoneal implants, tumoral rupture, or transected tumoral
thrombus
IV – hematogenic metastases (liver, lung, bone, brain) or extra-abdominal
lymph node metastasis
V – bilateral tumor
In both protocols, chemotherapy is based on vincristine and
dactinomycin for stage I and II with favorable histology and vin-
cristine, dactinomycin, and doxorubicin for stage III and IV with
favorable histology. Treatment of tumors with anaplastic histol-
ogy, advanced stages (III and IV), or greater-risk tumors also
includes cyclophosphamide or ifosfamide, carboplatin, and etopo-
side, eventually associated to radiation therapy (7). Stage V disease
(bilateral tumors) requires preoperative chemotherapy with vin-
cristine, dactinomycin, and eventually doxorubicin for 8 weeks,
followed by nephron sparing surgery. In the long-term follow-up,
the survival rates of both strategies, based in the surgical removal,
pre and/or post-operative chemotherapy and radiotherapy, are
equivalent (10, 11). The current trials of both protocols are trying
to minimize the late effects of treatment without compromising
the excellent overall survival (12).
The classical surgical procedure for the treatment of WT is open
radical nephrectomy through a transperitoneal access (10, 13). The
adrenal glands may be left “in situ,” if they are unchanged and can
be easily separated from the kidney; otherwise, they are removed.
Although extensive lymphadenectomy is not required, perihilar
and interaortocaval lymphnode samples must be obtained in all
cases, as they are necessary to adequate staging and planning of
post-operatory management. Failure to remove and evaluate lym-
phnodes increases the risk of local recurrence and significantly
decreases the 5-year survival rate (9, 14).
According to the consolidated experience in the treatment of
adult renal tumors, the well-known benefits of laparoscopic rad-
ical nephrectomy, namely reduced hospitalization and analgesic
requirement, as well as the better cosmetic result, were extended to
selected patients with WT. Although still considered experimental,
this technique has been employed with good results in several
centers in the treatment of unilateral tumors, with or without
neoadjuvant chemotherapy, without impairing the oncological
results (15–17).
Recent consideration has been given to nephron sparing
surgery in selected patients with unilateral WT. While long-term,
prospective data is not yet available, case series demonstrate preser-
vation of renal function and comparable oncologic outcomes after
partial vs. radical nephrectomy (18, 19).
In 5–7% of the cases,WT involves both kidneys. In this scenario,
besides complete removal of the tumor masses, treatment also aims
preservation of as much healthy renal tissue as possible, by means
of nephron sparing surgery (20). Preoperative tumor biopsy is
not always required. Neoadjuvant chemotherapy is recommended
for 6–12 weeks, after which the patient is re-evaluated by CT in
order to plan the best surgical approach. Possible alternatives
are bilateral partial nephrectomy or unilateral radical nephrec-
tomy associated to contralateral partial nephrectomy. The risk of
end-stage renal disease in bilateral WT is 5.4–12%, compared to
0.2–0.6% in unilateral tumors (12). Bilateral radical nephrectomy
is very rarely employed, as it implies immediate dialysis and later
renal transplantation.
In 4–10% of cases, WT may present with tumoral thrombus
in the renal vein, vena cava, or atrium, diagnosed by Doppler US,
CT, or MRI (10, 13). If the tumor thrombus is above the hepatic
veins, neoadjuvant chemotherapy is required to reduce the size of
the tumor and of the thrombus. Those of the inferior vena cava
may be extracted together with the tumor by incision of the vessel
below the diaphragm. For those that reach above the diaphragm,
thoracotomy, and cardiotomy with extracorporeal circulation is
necessary.
Post-operative treatment depends on the stage of the disease,
as well as the histological evaluation of the specimen and the lym-
phnodes obtained in surgery. As a rule, patients receive adjuvant
chemotherapy in all stages, with the eventual exception of chil-
dren younger than 2 years of age with stage I disease and tumors
with favorable histology weighing <550 g. All stage III patients
receive local irradiation, while in case of major tumoral rup-
ture a whole abdominal radiotherapy is necessary (11). In the
COG protocol, all patients with anaplastic histology also require
radiotherapy (10, 11).
The 5-year event-free survival is estimated in 87% for stage I
and 85–74% for stage II, 82% for stage III, and for stage IV it
decreases to 60–70% (21). Recurrence in patients with stage I or
II is associated to significant mortality even in favorable subtypes,
with overall survival dropping to 50% despite the use of more
intense chemotherapy in these relapsed cases (12).
Although significant success has been achieved in increasing
the overall 5-year survival rates to more than 90%, multimodal
therapy is associated to late adverse effects, which require long-
term monitoring of these patients (12). Around 0.7% of patients
with unilateral WT will develop renal failure, an incidence eight-
fold higher than that expected in the general population (22).
Fifteen years after diagnosis, the cumulative incidence of a sec-
ond malignancy is 1.6%, with risk factors including abdominal
radiotherapy as part of the initial or adjuvant treatment, with
or without chemotherapy for relapse (23). In the NWTSG Late
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Effects Study, the cumulative incidence of congestive heart failure
(CHF) 20 years after diagnosis of WT was 4% in patients whose
treatment plan included doxorubicin, with a direct dose–response
relationship (each 100 mg/m2 of doxorubicin exposure increased
the relative risk of CHF by 3.3). Furthermore, patients treated for
relapsed WT had a higher cumulative frequency of CHF compared
with patients without relapse (24).
MESOBLASTIC NEPHROMA
Congenital mesoblastic nephroma (CMN) is the most common
solid kidney tumor of the newborns, also called renal hamartoma
or leiomyomatous hamartoma. Usually, this tumor manifests itself
in the first 3 months of life, with a slight predominance in males,
as a painless abdominal mass. In some cases, it may be detected in
the antenatal US, accompanied by polyhydramnios and hydropsy.
It is also associated to early delivery.
At the time of detection, almost all CMNs are predominantly
localized in the kidney and perinephric or hilar soft tissue. The
imaging studies show a large, solid intrarenal mass that involves the
sinus, generally presenting cystic, hemorrhagic, and necrotic areas
(2). Histopathologically, they are predominantly monomorphic
neoplasms composed of spindled mesenchymal cells of fibroblas-
tic or myofibroblastic lineage. These are divided into two major
types: classic and cellular. Cytogenetic evaluation of this tumor
has shown that the cellular type is almost invariably associated
with abnormalities of the t (12;15) and 11+, whereas the classical
type rarely is. These abnormalities are also observed in congenital
fibrosarcoma (25).
Treatment is based on radical nephrectomy, and free margins
are necessary due to the infiltrative tendency of this tumor. Prog-
nosis is usually good, particularly in cases treated before the sixth
month of life Recurrences and metastasis occur in approximately
5–10% of all tumors (26).
RHABDOID TUMOR
This is a rare tumor, with 80% of cases occurring in children
before 2 years of age, mainly in boys, with a proportion to girls
of 1.5:1 (2, 10). Some patients present synchronous brain lesions
or atypical teratoid/rhabdoid tumor (AT/RT) that resemble primi-
tive neuroectodermal tumors, and have the same genetic mutation
(SMARCB1) found in the renal lesion (26). Approximately one-
third of newly diagnosed patients with RT have an underlying
genetic predisposition to tumors due to a germline SMARCB1
alteration. Family members may demonstrate incomplete pene-
trance and gonadal mosaicism, which must be considered when
counseling parents of patients with RT (27).
The common symptom is hematuria, but often there are signs
and symptoms related to metastatic spread to the lung, liver and
brain, that are present at the time of diagnosis in up to 80% of the
cases (2, 26). Preoperative biopsy is eventually required for patho-
logical diagnosis, but early radical nephrectomy is necessary for
cure. It is a very aggressive tumor, usually resistant to chemother-
apy and radiotherapy. The 4-year survival rate varies from 20 to
36% (10, 28).
CLEAR CELL SARCOMA
This tumor has a peak incidence between 1 and 4 years of age,
with a predominance of boys over girls of 2:1. There are no
known familiar or syndromic associations, nor bilateral cases
(2, 16). The main sign is a palpable abdominal mass, and 15–
60% of the cases present skeletal metastases at the time of
diagnosis, with pain as the main symptom. The imaging stud-
ies do not allow differentiation from WT. This tumor is sen-
sitive to chemotherapy, therefore it should be associated to
radical nephrectomy as the treatment of choice. The 5-year
relapse-free survival and overall survival rates reach as high as
79 and 86% respectively, for patients receiving 28–34 weeks of
chemotherapy (28, 29).
RENAL CELL CARCINOMA
Renal cell carcinoma (RCC) is the diagnosis in 2–5% of the pedi-
atric renal tumors. Between 0.5 and 2% of all RCC occur in patients
younger than 21 years of age, mainly between 9 and 15 years (2, 10,
26). It may be associated to the von Hippel–Lindau syndrome, in
which the tumors are multiple and have an earlier occurrence (2).
One population based study showed about 30% of cases associated
to underlying disorders, like tuberous sclerosis, neuroblastoma,
teratoma, Saethre–Chotzen syndrome, chronic renal failure, or
related diseases in their family (30).
Clinical presentation is similar to that of adults, with painless
macroscopic hematuria, flank pain, and palpable mass being the
most frequent symptoms. In general, RCC is smaller than WT
at the time of diagnosis. CT study shows a solid non-enhanced
intrarenal lesion, with areas of hemorrhage, necrosis, and calci-
fication, but clear differentiation from WT is not possible (2).
At presentation, more than two thirds of the patients have local-
ized disease. In metastatic disease, two thirds are in the regional
lymph nodes and one-third in distant organs, mainly lung, liver,
and brain (2, 30).
Childhood RCC differs histologically and biologically from
those of adults. The papillary form occurs in 20–50% of the cases,
while the rest is represented by the classical clear cell carcinoma
(10, 26). Genetic translocations are found in 30% of the RCC
in children, most of them involving the TFE3 gene on chromo-
some X p 11.2. Other biological targets of therapeutic interest
may be present and include c-Met, mTOR, and VEGRF. Morpho-
logically, these carcinomas resemble the conventional clear cell
tumor, but present areas of papillary architecture. They represent
a distinct class of renal carcinoma in the WHO classification (2,
10). Treatment consists in the complete removal of the tumor
by radical nephrectomy, either by open or laparoscopic access.
Lymphnode sampling is recommended for adequate staging. The
adrenal gland may be preserved in cases of lower pole tumor. Ini-
tial experience suggests that equivalent cure rates can be expected
from a nephron sparing approach in appropriately selected cases
(31). This tumor is resistant to chemotherapy or radiotherapy,
and the treatment of metastases is still a challenge. Angiogenesis-
inhibiting or immune-stimulating agents, like vaccines, interferon,
sorafenib, sunitinib, and sirolimus, are possible therapeutic alter-
natives, with limited temporary results. Event-free survival and
overall survival rates at 5 years reach 96% for localized RCC, 69
and 75% for regional lymph node-positive patients, 25 and 33%
for patients with distant metastases, respectively (30). Recent stud-
ies show that survival in children with lymphatic spread only is
better than in adults (10, 28).
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MEDULLARY CARCINOMA
Described recently in 1995, it affects carriers of sickle-cell dis-
ease trait. It presents a very aggressive behavior, with frequent
metastases and a mortality rate close to 100%. Treatment is
based on radical nephrectomy, as it is unresponsive to chemo or
radiotherapy (28).
Other less common renal malignancies of childhood include
the anaplastic sarcoma, cystic nephroma, primitive neuroectoder-
mal tumor, desmoplastic small round cell tumor, as well as the
intrarenal neuroblastoma. Adenomas, lipomas, lymphomas, and
angiomyolipomas are also described in children. In these, as in
the previously described tumors the preoperative imaging studies
are mostly unable to establish the preoperative diagnosis. Their
treatment is mostly based on radical nephrectomy (12).
RHABDOMYOSARCOMA
Rhabdomyosarcoma (RMS) is a malignant tumor that originates
from the embryonic mesenchymal cells that give origin to the
striated musculature. It may surge in various sites in the body,
even where the striated muscle is not usually present. They rep-
resent 4–8% of the malignant tumors in patients younger than
15 years of age, and around 21% of them rise in the genitourinary
tract, mainly in the bladder, prostate, vagina, and the paratesticular
region (32).
The annual incidence in the United States is 4.5 cases per mil-
lion children younger than 15 years of age. There is a bimodal
age distribution with a peak incidence in the first 2 years of life
and another in adolescence. Etiology is unknown, but a possi-
ble explanation is the regulatory disruption of striated muscle
progenitor cell growth and differentiation (33). Some environ-
mental factors are associated to an increased risk for developing
the disease, like paternal smoking habit, advanced maternal age,
intrauterine exposition to radiation, and use of illicit drugs by
the mother. A genetic predisposition is found in the Li–Fraumeni
syndrome and neurofibromatosis. Compared to the general popu-
lation, patients with RMS have an increased incidence of associated
congenital malformations (32 vs. 3%) (34, 35).
Rhabdomyosarcoma includes a heterogeneous group of
tumors, that present two main histologic variants: the embryonal,
which is predominant, and the alveolar. The embryonal RMS is
subdivided into spindle cell and the botryoid sarcoma subtypes.
Spindle cell histology is common in paratesticular lesions, whereas
botryoid lesions are polypoid masses that fill the lumen of the
bladder and vagina (33, 35). Embryonic RMS generally presents
a favorable prognosis. Alveolar histology, which is characterized
by two genetic reciprocal translocations PAX3-FOXO1 and PAX7-
FOXO1, is more prevalent in adolescents and confers a lesser
chance of cure due to the high rate of local recurrence (32, 34, 36).
The clinical symptoms of genitourinary RMS depend on the
site of the lesion. Paratesticular RMS presents as unilateral painless
scrotal mass distinct from the testis, which is fortuitously palpated.
At diagnosis, retroperitoneal lymph node extension is detected in
20–40% of these patients. Bladder or prostatic tumors generally
cause voiding symptoms like frequency, dysuria and hematuria,
but urinary retention is the most frequent. On physical examina-
tion, a pelvic mass can be palpated. Girls with primary tumor in
the vagina or uterine cervix may present in the first years of life
with vaginal bleeding or discharge and occasional exteriorization
of the polypoid mass through the vulva (34, 35).
Patients with suspected bladder, prostate, and vaginal tumors
require complete laboratorial and imaging studies. MRI provides
excellent definition of the primary tumor and surrounding tissues,
while CT is useful for evaluation of bone erosion and abdominal
lymphadenopathy. Bone scan is necessary for the search of skeletal
metastases, while the PET-scan is useful in the evaluation of the
primary lesion as well as regional and distant metastases (33, 37).
Diagnosis is confirmed by biopsy or resection of the tumor.
Paratesticular tumors are best managed initially by radical
orchiectomy through the inguinal approach.
According to the recommendations of the Intergroup RMS
Study Group, most boys older than10 years of age should then
undergo staging ipsilateral retroperitoneal template lymph node
dissection followed by multiagent chemotherapy and radiother-
apy. In children aged <10 years, however, PET-CT may be sensi-
tive for the identification of metastatic retroperitoneal lymphatic
metastases, thus reducing the need of lymphadenectomy (38).
Radiotherapy is beneficial in patients with lymph node-positive
disease (39).
Bladder or prostatic lesions require cystoscopic evaluation and
biopsy, but when these are unsuccessful, needle biopsy or open
surgery may be necessary. Protruding vaginal masses are eas-
ily biopsied. All samples must be submitted to histopatholog-
ical, immunohistochemical, cytogenetic, and molecular studies.
Presently, the main therapeutic objective in vesico-prostatic or
vaginal-uterine RMS is to ensure cure with maximal functional
and anatomical preservation of the involved organs, avoiding
mutilating procedures that are associated to increased morbidity.
After imaging and pathological studies, neoadjuvant chemother-
apy is initiated. With size reduction of the tumor, definitive
but conservative surgical resection is recommended. The role of
surgery is decisive in the success of the treatment, since local con-
trol of the disease correlates with prognosis. Complete resection of
the primary tumor is ideal. Microscopic evaluation of the surgical
margins, as well as lymphnode sampling for staging, is highly rec-
ommended. Adjuvant chemo and radiotherapy are then initiated
according to the stage of the disease and the success of surgery (40).
Rhabdomyosarcoma is staged by the Soft Tissue Sarcoma Com-
mittee with a disease-specific TNM staging system (Tables 3 and 4)
(41). Considering the stage, group and histology, patients are
assigned to low, intermediate, or high-risk groups. Those with
paratesticular and vaginal RMS with embryonic histology and
complete resection, even with microscopic residual, are consid-
ered low-risk patients. Intermediate-risk patients include bladder
and prostatic RMS, as well as those with gross residual disease.
High-risk patients are those with metastatic disease (40–42).
Patients with positive lymph nodes, also when detected by
PET-CT, must be submitted to more intensive chemotherapy and
eventual radiotherapy. This multimodal approach ensures sur-
vival rates of 90% (35, 43). In tumors that involve the bladder
and prostate, around 70% are originated in the bladder. In most
of these cases, neoadjuvant chemotherapy and radiation allow a
bladder sparing surgery. It is possible to achieve disease-free sur-
vival with preservation of vesical function by partial cystectomy in
50–60% of cases, particularly in those with tumors arising in the
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Table 3 | Preoperative staging of rhabdomyosarcoma (41).
Stage Organ Tumor (T) Size Lymphnode
(N)
Metastases
(M)
I Paratesticular,
vaginal uterine
T1 or T2 a, b N0, N1, Nx M0
II Bladder, prostate T1 or T2 a N0, Nx M0
III Bladder, prostate T1 or T2 a N1 M0
b N0, N1, Nx
IV All T1 or T2 a, b N0 or N1 M1
T1, tumor confined to site of origin (a, diameter <5 cm; b, diameter >5 cm).
T2, local infiltration, extension, or adherence (a, diameter <5 cm; b, diameter
>5 cm).
N0, negative regional lymph nodes; N1, positive regional lymph nodes.
Nx, lymph nodes status unknown; M0, no distant metastases; M1, positive
distant metastases.
Table 4 | Post-operative classification of rhabdomyosarcoma (41).
Group 1 Localized disease, completely removed, without
microscopic residual
A Confined to the site of origin, but completely removed
B Infiltration beyond site of origin, but completely removed
Group 2 Total macroscopic resection
A Macroscopic resection with evidence of microscopic
residual lesion
B Regional disease with lymph node extension, completely
resected without microscopic residual lesion
C Local microscopic residual lesion and/or residual lymph
node extension
Group 3 Incomplete resection or biopsy, with residual mass
Group 4 Distant metastases
bladder dome. Larger tumors, as well as those originating from the
bladder base or prostate and also those resistant to neoadjuvant
chemotherapy eventually require extensive resection with ureteral
reimplantation, cystectomy, or cystoprostatectomy, with need of
urinary diversion (44). In general, tumors that originate from the
vagina respond well to chemotherapy, rarely requiring procedures
like partial vaginectomy or vaginectomy with hysterectomy. Late
complications like vaginal stenosis, ureteral obstruction, intesti-
nal stricture or fistula, and ovarian failure are often observed after
multimodal therapy (42).
Chemotherapy is based in the use of vincristine, actinomycin
D, and cyclophosphamide for low-risk patients. The group of
intermediate-risk may receive the same drugs associated to ifos-
famide or etoposide. High-risk patients must be treated with a
combination of ifosfamide, etoposide, and doxorubicin. The com-
bination of vincristine and irinotecan is useful in metastatic dis-
ease. The aim-therapy formTOR receptors, employing rapamycin,
temsirolimus, and everolimus, as well as IGF-1R, is still under
investigation. Children with low-risk tumors have 5-year survival
rates of 90%, while those with intermediate-risk reach 55–70%
and those with high-risk <50% (41–43, 45).
TRANSITIONAL CELL CARCINOMA
Transitional cell carcinoma of the bladder in children is very
rare, with about 150 patients younger than 20 years presented in
the literature, only 20% of them in the first 10 years of age. It
predominates in white children with a male-to-female ratio of
3:1 (46–48).
Asymptomatic macroscopic hematuria is the most common
onset symptom. Imaging studies with US followed by cystoscopy
are the ideal diagnostic tools. There are few isolated reports of
upper urinary tract involvement, therefore the kidneys must always
be evaluated by ultrasound. Most lesions are located in the trigone,
and the predominant histological pattern is papillary and non-
invasive. Endoscopic resection is the standard treatment, being
effective in all cases of localized disease. Follow-up includes regu-
lar ultrasound evaluation and urinary cytology every 6 months in
the first 2 years and cystoscopy once a year. Recurrence is described
in 13% of the patients, and progression to invasive disease with
muscular involvement occurs in 10–15% of cases (48, 49).
TESTICULAR TUMORS
Testicular tumors are less frequent in childhood than in post-
pubertal age. The annual incidence is 5.9/100,000 boys younger
than 15 years of age, with the peak incidence in the first 3 years of
life. They represent 2% of the pediatric tumors, and two thirds of
them are of benign nature (Table 5) (50, 51).
Increase in the scrotal volume and palpation of a hardened
painless testicular mass are the initial findings in 88% of the
patients. In some cases, a hydrocele or hernia may lead to the diag-
nosis. Inflammatory processes, as well as cysts and particularly
testicular torsion must be excluded (53). Physical examination is
important, in order to evaluate signs of virilization. The preferred
imaging modality for these tumors is doppler US, that identi-
fies the presence, size, and exact location of the mass, but does
not differentiate between benign and malignant lesions. Never-
theless, some tumors have specific US characteristics, like the
epidermoid cysts and the teratoma. Alpha-feto-protein (AFP) is an
important tumor marker, and has increased blood levels in most
cases of malignant prepuberal testicular tumors. Human chorionic
gonadotropin (β-HCG) blood levels are rarely increased in these
tumors. In confirmed malignant tumors, it is necessary to search
for retroperitoneal and pulmonary metastases with CT imaging.
Staging is based in image studies and tumoral markers, as well as
the pathological findings (Table 6).
Surgical treatment usually begins with radical orchiectomy,
which is recommended whenever the AFP is elevated. It is per-
formed through an inguinal incision with control of the vessels
at the internal inguinal ring and removal of the testis without
violating the vaginal tunic. If the AFP is normal, the tumor is
probably benign, as in cases of teratoma and epidermoid cyst. A
partial orchiectomy may be then considered, requiring protection
of the operative field, clamping of the pedicle, incision of the vagi-
nal tunic and albuginea, and careful enucleation of the mass. The
tunics are then closed, and the testis reinserted in the scrotum after
clamp removal (52, 54).
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Table 5 | Relative frequency of the different tumor types registered in
the “prepuberal testis tumor registry” (52).
Type of tumor N % Behavior
Yolk sack tumor 244 62 Malignant
Teratoma 92 23 Benign
Indifferentiated stromal 16 4 Occasionally malignant
Epidermoid cyst 13 3 Benign
Juvenile cell of granulosa 11 3 Benign
Sertoli cell 10 3 Malignant in older children
Leydig cell 5 1 Benign
Gonadoblastoma 4 1 Usually benign
Table 6 | Children’s Oncology Group (COG) staging system for
malignant testicular tumors of childhood (53).
Stage Extent of disease
I Limited to testis, completely resected by high inguinal
orchiectomy. Absence of clinical, radiographic, or histologic
evidence of residual disease
II Transcrotal biopsy, microscopic disease in scrotum or in
spermatic cord (<5 cm from proximal end). Tumor markers
fail to normalize or decrease with appropriate half-life
III Retroperitoneal lymph node involvement, but no visceral or
extra-abdominal involvement. Lymph nodes >4 cm by CT, or
>2 cm and <4 cm with biopsy proof
IV Distant metastases, including liver
In the post-operative period, the patient is observed in case of
benign tumors. In case of malignancy with stage I testes tumors,
surgery alone presents excellent survival rates, with recurrence
in 15.5% of the patients. Stage II disease is associated with 75%
recurrence rate. In both cases, recurrence is successfully treated
with chemotherapy based on cisplatin, etoposide, and bleomycin.
Higher stages of the disease have also excellent prognosis, with
association of surgery and chemotherapy (52).
YOLK SACK TUMOR
It is the most common testis tumor in children younger than
2 years of age, presenting as a solid testicular mass associated to
increased levels of AFP (51). Most cases present with localized
disease, and only 4–6% have retroperitoneal or pulmonary metas-
tases, which are suspected by persistently increased levels of AFP
after orchiectomy and evidenced by imaging studies.
Radical orchiectomy is generally curative in localized disease,
therefore if the post-operative blood levels of AFP, whose half-life
5–7 days, are normal and the imaging studies are normal, there is
no need of adjuvant therapy (55). Cases with persistently elevated
APF or confirmed metastases must be treated with chemotherapy,
presenting 6-year survival rates near 100% (55–57).
TERATOMA
It is the second most frequent prepuberal testicular tumor, with a
peak incidence at 13 months of age (55). Contrary to those that
occur in the adult age, prepuberal teratomas are usually benign
(58). Although not specific, the US finding of cysts within the
tumor may suggest the diagnosis. As mentioned before, conserva-
tive surgical treatment is recommended in most cases, with careful
resection of the nodule and preservation of the normal testicu-
lar tissue. However, in patients with signs of virilization, radical
orchiectomy is indicated (59).
EPIDERMOID CYST
These lesions are composed entirely of keratin producing epithe-
lium, which is easily identified in most cases by US evaluation,
due to the peculiar aspect of concentric layers similar to that of
an onion (60). This tumor probably represents a monodermal ter-
atoma. It is usually benign and is best treated with conservative
surgery (50, 51, 54).
STROMAL TUMORS
These are very rare tumors in this age group. They are represented
by the following four lineages (61):
– Leydig cell tumor : usually benign, it occurs between 5 and
10 years of age and can manifest with virilization. It may be
treated with partial orchiectomy.
– Sertoli cell tumor : occurs between 4 months and 10 years of age.
Although hormonally inactive in most cases, it can occasion-
ally cause gynecomasty or early puberty. There are no reports
of metastases in this age group, but older boys can present
disseminated disease. Accordingly, simple orchiectomy may be
curative in younger patients, but in older boys imaging studies
are necessary to identify metastatic disease.
– Tumor of the juvenile cell of the granulosa: it is named by the
presence of cells that resemble the granulosa layer of the juve-
nile ovary. Occurs mainly in the first semester of life and is
associated to abnormalities of the Y chromosome. There may
be an association with genital ambiguity. The usual treatment
is simple orchiectomy.
– Undifferentiated stromal tumor : it presents areas of stromal neo-
plasia associated to undifferentiated areas of fusiform cells with
high degree of mitoses. Most cases are benign, but in older
boys they may present malignant behavior. Routine treatment
is orchiectomy, but adjuvant chemotherapy may be necessary in
cases of confirmed malignancy.
GONADOBLASTOMA
Patients with disorders of sexual differentiation present an
increased incidence of gonadal tumors in the presence of the
Y chromosome, particularly when associated to intra-abdominal
cryptorchism or disgenetic gonads. Although more frequent in the
post-puberal age, they may occur in childhood. They are usually
benign and asymptomatic, but may be associated to virilization.
If not removed, they may progress to disgerminomas, that present
malignant behavior. Prophylactic laparoscopic gonadectomy is
recommended in these cases (61, 62).
ADRENAL TUMORS
The adrenal gland may be site of several types of tumors, either
benign or malignant, primary, or metastatic. Primary adrenal
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tumors originate from the medulla or cortex, and can be hyper
or non-functioning. The group of primary medullary neo-
plasms include the neuroblastoma, ganglioneuroblastoma, and
ganglioneuroma, which are collectively referred as neuroblastic
tumors, as well as the pheochromocytoma (63). Tumors origi-
nating from the cortex include the adrenocortical adenoma and
carcinoma. In children, the most common lesions are neurob-
lastomas and cortical adenomas, with pheochromocytomas and
cortical carcinomas occurring more rarely (64).
Diagnosis of adrenal tumors is suspected in children with
hormonal abnormalities. Routine US imaging may disclose non-
functioning tumors in the minority of patients. Clinical evaluation
must include imaging and hormonal studies. Abdominal CT or
MRI confirm the side, size, and extension of the tumor, as well as
the eventual presence of vascular thrombus, infiltration of adjacent
structures and distant metastases.
NEUROBLASTIC TUMORS
The adrenal is the most common site of tumors originated from the
ganglionar cells. These tumors include the neuroblastoma, which
is the most malignant, due to the presence of undifferentiated
small round cells, the ganglioneuroma, that is a more mature neo-
plasm, with a benign behavior, and the ganglioneuroblastoma,
which presents mixed histology and has an intermediate behav-
ior. Both neuroblastoma and ganglioneuroblastoma occur more
frequently in children, while the ganglioneuroma presents more
often in adolescents and young adults (63).
Neuroblastoma is the most common extracranial solid neo-
plasm in children, arising in the adrenal or in any segment of
the sympathetic plexus. In 75% of the cases it is found in the
abdomen, being one-third in the medulla of the adrenal gland.
It is the most frequent malignant adrenal tumor in childhood,
occurring more often during the first 10 years of life, 80% of
them in children younger than 5 years of age. It may be diagnosed
antenatally or in the first months of life on routine US examina-
tions, but is most often detected as a palpable abdominal mass.
Symptoms are related to the mass effect, with pain and abdomi-
nal distension, invasion of adjacent organs, metastatic disease or
abnormal hormonal production of catecholamines, or vasoactive
intestinal polypeptides. Opsomyoclonus or cerebellar ataxia has
been observed in up to 4% of patients (63). The tumor consists
mainly of primitive neuroblasts, and has a tendency to infiltrate
and sometimes invade the adjacent organs and vessels, as well as
to present hemorrhage and necrosis. Imaging studies with CT or
MRI are necessary to stage the local extension of the lesion, while
123I-meta-iodobenzylguanidine scintigraphy is useful to identify
distant metastases, mainly to the lymph nodes, bone marrow, liver,
and skin, which are present in more than half of the patients at the
time of diagnosis (63). Bone metastases are frequently detected in
skull, vertebrae, and long bones (63). The prognosis for adrenal
neuroblastoma depends mainly on the age of the patient and stage
of the disease. In very small children and infants these tumors
may spontaneously regress and even disappear (65). Except in
this very early age group, in which conservative management may
be employed, adrenalectomy is the procedure of choice, either by
open or laparoscopic approach. The prognosis is dismal for chil-
dren older than 18 months of age, with metastatic disease. Tumors
presenting amplification of the MYCN oncogene have a bad prog-
nosis and are considered as high-risk group (65). For these patients
surgery with chemoradiotherapy, stem cell transplantation, as well
as anti-disialoganglioside (GD2) immunotherapy plus cytokines
may improve survival (66).
Ganglioneuroblastomas and ganglioneuromas occur more
rarely, the former with similar symptoms as the neuroblastoma,
the later more often asymptomatically. While differential diagno-
sis is difficult by imaging studies, urinary catecolamine levels are
usually not increased in these tumors (63). Surgical removal is the
standard treatment.
PHEOCHROMOCYTOMA
This neoplasm occurs very rarely in children and represents<1%
of all tumors in this age group. It usually occurs in older children,
at a mean age of 11 years. Compared to adults, there is an increased
tendency of bilaterality, rarely being malignant. Most of these
lesions occur sporadically, but a familial heritage is possible, par-
ticularly in syndromes like Multiple Endocrine Neoplasia (MEN)
type-2 and diseases like von Recklinghausen, von Hippel–Lindau,
and Sturge–Weber (63).
Pheochromocytoma generally manifests itself by the increase
in blood pressure levels, sweating, tachycardia, headaches, visual
blurring, flushing, and diarrhea, secondary to excess production
of adrenal epinephrine and norepinephrine, as well as vasoactive
intestinal polypeptides. Diagnosis is suspected by the increased
seric and urinary levels of cathecolamines and metanephrines,
and confirmed by the finding of adrenal masses by US, CT,
or MRI. 123I-meta-iodobenzylguanidine scintigraphy is useful to
exclude multifocal disease. In confirmed cases, initial treatment
with alpha- and beta-blockers is recommended to control blood
pressure and heart rate. Surgical removal of the tumor must be
performed under carefully controlled anesthesia with invasive
continuous blood pressure and heart rate monitoring, as well
as judicious use of nitroprusside and beta-blockers (63). After
removal, intensive hydration is necessary to prevent hypotension.
Hypertension and other symptoms usually disappear afterward,
but control laboratory exams are necessary to identify residual
lesions or recurrence.
Although complete removal of the affected adrenal is the stan-
dard procedure, partial laparoscopic adrenalectomy, or tumorec-
tomy have gained acceptance for small tumors, particularly in the
hereditary syndromes described before. The obvious advantage of
partial adrenalectomy is that it may avoid the need of hormonal
replacement in cases of bilaterality, although the risk of recurrence
in the remnant tissue is also increased (63, 67). The laparoscopic
approach enables both total and partial adrenalectomy also in
children (68).
ADRENOCORTICAL TUMORS
Primary adrenocortical tumors (ACT) are rare in children, with
a worldwide incidence of 0.3/1 million per year before the
age of 15 years. In southern Brazil the prevalence is 15 times
higher than in other parts of the world, due to TP53 R337H
germline mutations in the population of that area (69, 70). These
tumors occur more often before 5 years of age, with a female
predominance.
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Contrary to adults, in children the ACT are generally detected
due to the hormonal abnormalities, including virilization in girls,
precocious puberty in boys, hypertension, and less often Cushing’s
syndrome. Increased serum levels of adrenal hormones raise the
suspicion of ACT, which are confirmed by CT or MRI, that pro-
vide information regarding size and local extension of the tumor,
as well as vascular invasion and distant metastases (63).
The characteristics of pediatric ACT vary considerably. Labo-
ratory findings, clinical and hormonal features, as well as tumor
size are not able to distinguish adenomas from carcinomas before
surgery (71). Small homogeneous masses are usually benign while
larger masses with areas of hemorrhage, necrosis, and calcifica-
tion more often present malignant behavior (63). Although it
is difficult to define what is a large tumor in a child, function-
ing tumors that present heterogeneity, infiltration of vessels or
neighboring organs, and a slow wash-out in the image studies
are to be removed more expeditiously due to increased risk of
malignancy.
After clinical investigation, surgical treatment with radical
resection is the treatment of choice, and the hormonal distur-
bances disappear soon after the removal of the affected gland (64).
Laparoscopic adrenalectomy has been performed in children with
benign ACT with excellent results (68).
Histologic differentiation of ACT in children is more diffi-
cult to define than in adults (72, 73). The prognosis is good in
young patients with completely removed, non-metastatic, and
non-infiltrative lesions. Confirmed cases of carcinoma have an
increased risk of recurrence and mortality. COG study ARAR0332
aims to clarify how effective surgery alone is for patients with
early stages of ACT, as well as to define the advantages of a
more radical surgery with extended lymphadenectomy in selected
patients. The efficacy of the combination of mitotane with cis-
platin, etoposide, and doxorubicin in advanced stages is also being
studied (64, 74, 75).
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